26 September 2016 16:00
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 26 September 2016, the interest of Sean Bohen, a person discharging
managerial responsibilities, in the ordinary shares of AstraZeneca PLC changed
as detailed below.
The change in interest relates to the vesting of an award of AstraZeneca
American Depositary Shares (ADSs) made in September 2015 under the AstraZeneca
Restricted Share Plan.
One ordinary share equals two ADSs.
After sufficient vested shares were withheld to satisfy certain tax obligations
arising on the vesting, Mr Bohen has become beneficially entitled to and has
received 12,385 ADSs into a personal brokerage account.
For tax purposes, the fair market value of the shares at vest was $33.97 per ADS
being the closing price on the last trading day preceding the vesting day.
The attached notification, made in accordance with the requirements of the EU
Market Abuse Regulation, gives further detail.
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1 Details of the person discharging
managerial responsibilities / person
closely associated
a) Name Sean Bohen
2 Reason for the notification
a) Position/status Executive
Vice
-President,
Global
Medicines
Development
and Chief
Medical
Officer
b) Initial notification /Amendment Initial
notification
3 Details of the issuer, emission
allowance market participant, auction
platform, auctioneer or auction monitor
a) Name AstraZeneca
PLC
b) LEI Not
applicable
4 Details of the transaction(s): section
to be repeated for (i) each type of
instrument; (ii) each type of
transaction; (iii) each date; and (iv)
each place where transactions have been
conducted
a) Description of the financial AstraZeneca
instrument, type of instrument PLC American
Identification code Depositary
Shares
CUSIP:
046353108
b) Nature of the transaction Acquisition
of
AstraZeneca
American
Depositary
Shares
pursuant to
the vesting
of an award
under the
AstraZeneca
Restricted
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
12,385
$33.97
d) Aggregated information - Aggregated Not
volume - Price applicable -
single
transaction
e) Date of the transaction 26 September
2016
f) Place of the transaction New York
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on
the discovery, development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas - Respiratory and
Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company
is also active in inflammation, infection and neuroscience through numerous
collaborations. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
Neil Burrows UK/Global +44 203 749 5637
Vanessa Rhodes UK/Global +44 203 749 5736
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
UK
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Nick Stone Respiratory & Autoimmunity +44 203 749 5716
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris Infection & Neuroscience +44 203 749 5711
US
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Mitchell Chan Oncology +1 240 477 3771
Toll-free +1 866 381 7277
Adrian Kemp
Company Secretary
AstraZeneca PLC
-ENDS-
Director/PDMR Shareholding
| Quelle: AstraZeneca PLC
Anhänge
